Retrieve available abstracts of 253 articles: HTML format
Single Articles
August 2025
CASTILLO LC, Belenchon IR, Sanz IP, Marenco RS, et al Multicenter External Validation and Optimization of a Proposed Nomogram for
Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence.
Prostate. 2025;85:1016-1023. PubMedAbstract available
BERTINI A, Stephens A, Finocchiaro A, Silvia V, et al Association of Area of Deprivation Index With Active Surveillance (AS)
Utilization and Adherence to as Guidelines: Results From a Contemporary North
American Cohort.
Prostate. 2025;85:1024-1035. PubMedAbstract available
July 2025
SHARIFI MN, Heninger E, Bootsma ML, Recchia EE, et al Transcriptomic Signatures of Monocyte-Derived Macrophages Associate With Androgen
Receptor Pathway Inhibitor Progression in Prostate Cancer.
Prostate. 2025 Jul 2. doi: 10.1002/pros.70000. PubMedAbstract available
June 2025
GRUBER I, Koelbl O, Meier MM Late Bowel Symptoms in Long-Term Survivors of Prostate Cancer Following
Radiotherapy.
Prostate. 2025 Jun 24. doi: 10.1002/pros.70004. PubMedAbstract available
GRUTMAN AJ, Jing Y, Ng DK, Landis PK, et al History of Vasectomy Is not Associated With Prostate Cancer Progression in Men on
Active Surveillance.
Prostate. 2025 Jun 23. doi: 10.1002/pros.70001. PubMedAbstract available
TAKAHASHI T Evidence and Rationale for Prostate Cancer Screening.
Prostate. 2025 Jun 22. doi: 10.1002/pros.70002. PubMed
LEMSTER AL, Grunhagen S, Schmalfeld S, Lenz F, et al Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in
Metastatic Prostate Cancer.
Prostate. 2025 Jun 12. doi: 10.1002/pros.24925. PubMedAbstract available
YANG YJ, Zeng C, Schaffer KR, Tran TC, et al Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in
Prostate Cancer Patients of the All of Us Research Program Cohort.
Prostate. 2025 Jun 11. doi: 10.1002/pros.24913. PubMedAbstract available
FUKUSHIMA T, Goto K, Nakano Y, Tasaka S, et al Comprehensive Genomic Profiling Testing for Castration-Resistant Prostate Cancer
in Advanced Elderly Patients: A Single-Center Retrospective Cohort Study.
Prostate. 2025 Jun 10. doi: 10.1002/pros.24926. PubMedAbstract available
HORVATH A, Blasszauer C, Komka I, Reibl D, et al Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First-
and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer.
Prostate. 2025 Jun 8. doi: 10.1002/pros.24923. PubMedAbstract available
XUE C, Ko HK, Shi K, Pittsenbarger J, et al Understanding Enzalutamide-Resistance Based on a Functional Single-Cell Approach.
Prostate. 2025;85:888-899. PubMedAbstract available
MIURA Y, Yoneyama T, Yamamoto H, Suzuki H, et al Analytical and Real-World Clinical Characterization of S2,3PSA% Test in MRI
Fusion Targeted Prostate Biopsy Population.
Prostate. 2025;85:869-887. PubMedAbstract available
May 2025
ODERDA M, Orlando G, Calleris G, Capella G, et al Role of Cell-Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2-ERG
Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under
Active Surveillance.
Prostate. 2025 May 29. doi: 10.1002/pros.24921. PubMedAbstract available
YANG P, Yang B A Multimarker Model for Prostate Cancer Risk Assessment: Improving Diagnostic
Accuracy Beyond PSA.
Prostate. 2025 May 26. doi: 10.1002/pros.24920. PubMedAbstract available
ONAL C, Elmali A, Demirhan B, Guler OC, et al SBRT Boost in Prostate Cancer: Progress Made, Questions Remain.
Prostate. 2025 May 26. doi: 10.1002/pros.24919. PubMed
FENG F, Xu Z Bimodal Imaging: Detection Rate of Clinically Significant Prostate Cancer Is
Higher in MRI Lesions Visible to Transrectal Ultrasound.
Prostate. 2025 May 23. doi: 10.1002/pros.24839. PubMed
XU J, Lu J, Gielzak M, Lilly Zheng S, et al Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes
Recommended by NCCN Guidelines.
Prostate. 2025 May 22. doi: 10.1002/pros.24918. PubMedAbstract available
MIURA H, Hamaya T, Yoneyama T, Shimoyama T, et al The Effects of the Blood-Based S2,3PSA% Test on Prostate Cancer Screening: A
Novel Approach to Reduce the Need for MRI and Unnecessary Biopsies.
Prostate. 2025 May 22. doi: 10.1002/pros.24917. PubMedAbstract available
QU LG, Vaselkiv JB, Perera M, Mucci L, et al Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER
Investigation.
Prostate. 2025 May 20. doi: 10.1002/pros.24915. PubMedAbstract available
AGUILERA M, Klinkebiel DL, Williams V, Rovatti J, et al Altered Ten Eleven Translocation Methylcytosine Dioxygenase Expression and DNA
Hydroxymethylation in a Mouse Model of Prostate Cancer.
Prostate. 2025 May 11. doi: 10.1002/pros.24912. PubMedAbstract available
MANDL A, Zahurak ML, Metri NA, Shore ND, et al Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A
Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the
SOD2 Ala/Ala Variant.
Prostate. 2025 May 5. doi: 10.1002/pros.24903. PubMedAbstract available
SAPERSTEIN L, Rowe SP, Gorin MA, Pienta KJ, et al Impact of Concomitant Hormone Therapy on the Diagnostic Performance of
(18)F-Piflufolastat PET/CT in Prostate Cancer Patients: A Sub-Group Analysis of
OSPREY Cohort B.
Prostate. 2025 May 4. doi: 10.1002/pros.24909. PubMedAbstract available
RAHBAR K, Kidd M, Prasad V, David Rosin R, et al Clinical Sensitivity and Specificity of the PROSTest in an American Cohort.
Prostate. 2025;85:558-566. PubMedAbstract available
ARRIAGA-IZABAL D, Morales-Lazcano F, Canizalez-Roman A Development and Validation of a Predictive Model of Prostate Screening
Compliance: A Nationwide Population-Based Study.
Prostate. 2025;85:513-523. PubMedAbstract available
LIN YH, Lin KJ, Shao IH Androgen Deprivation Therapy: Mitochondrial Dysfunction and Metabolic Impacts in
Prostate Cancer.
Prostate. 2025;85:719-720. PubMed
DIEUDONNE ZOJ, Gebreselassie KH, Mohammed TO, Khalid A, et al Current Status of Prostate Biopsy in Africa: Are We Ready for a Targeted Biopsy?
Prostate. 2025;85:638-645. PubMedAbstract available
ASIRI IM, Chen RC, Master V, Mi L, et al Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and
Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway
Inhibitors.
Prostate. 2025 May 1. doi: 10.1002/pros.24902. PubMedAbstract available
April 2025
GOUVEIA A, Mesci A, Isfahanian N, Dayes I, et al Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic
Body Radiotherapy Boost Versus Conventional Fractionation External Beam
Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.
Prostate. 2025 Apr 27. doi: 10.1002/pros.24905. PubMedAbstract available
BACLE C, Mazancourt ES, Abid N, Ruffion A, et al Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for
Prostate Cancer in Patients With Lower Urinary Tract Symptoms.
Prostate. 2025 Apr 24. doi: 10.1002/pros.24906. PubMedAbstract available
SRUTHI KK, Ummanni R Valosin-Containing Protein (VCP/p97) Mediates Neuroendocrine Differentiation in
Prostate Cancer Cells Through Pim1 Signaling Inducing Autophagy.
Prostate. 2025 Apr 23. doi: 10.1002/pros.24900. PubMedAbstract available
DEE EC, Iyengar R, Narayan A, Feliciano EJG, et al National Cancer System Characteristics and Prostate Cancer Outcomes: An Analysis
of Global Data.
Prostate. 2025 Apr 15. doi: 10.1002/pros.24901. PubMedAbstract available
SHIMOMURA T, Urabe F, Muramoto K, Yanagisawa T, et al Evaluating CRPC Definition: Comparing Upfront ARSI and Conventional Hormonal
Therapy for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in Real World
Propensity Score Matched Cohort.
Prostate. 2025 Apr 8. doi: 10.1002/pros.24898. PubMedAbstract available
SHIMOMURA T, Otsuka N, Urabe F, Muramoto K, et al PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for
Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive
Prostate Cancer (mHSPC) in Real-World Analyses?
Prostate. 2025 Apr 6. doi: 10.1002/pros.24885. PubMedAbstract available
OKAMURA T, Izumi K, Kurokawa S, Shima T, et al Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder
Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE
Study.
Prostate. 2025 Apr 3. doi: 10.1002/pros.24897. PubMedAbstract available
PAE S, Sakamoto S, Zhao X, Tamura T, et al LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate
Cancer Patients After Radiotherapy.
Prostate. 2025 Apr 2. doi: 10.1002/pros.24899. PubMedAbstract available
ZHANG X, Sang W, Hong X, Qu H, et al Effect of Dendritic Cells Injection After Radical Prostatectomy on Prostate
Cancer in Mice.
Prostate. 2025 Apr 2. doi: 10.1002/pros.24892. PubMedAbstract available
BARABAN EG, Vlachou E, Patel S, Kates M, et al Nectin-4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study.
Prostate. 2025;85:443-447. PubMedAbstract available
GAMAL A, Moschovas MC, Jaber AR, Saikali S, et al Functional and Oncological Outcomes of Very Large Prostate Sizes Post Robotic
Radical Prostatectomy: A Propensity Score-Matched Analysis.
Prostate. 2025;85:456-462. PubMedAbstract available
TANG L, Wu M, Chen K, Gao F, et al Automatic MRI-TRUS Fusion Technique for Transperineal Biopsy Guidance: From
Preoperative Planning to Intraoperative Navigation.
Prostate. 2025;85:424-432. PubMedAbstract available
SRIDHAR S, Abouelfetouh Z, Codreanu I, Gupta N, et al The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating
Prostate Adenocarcinoma: A Partially-Blinded Retrospective Study of a
Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and
Application of PI-RADS or
Prostate. 2025;85:413-423. PubMedAbstract available
March 2025
MANTENA RV, Bhadouriya R, Jain U, Patel TA, et al Treatment Noncompletion and Shorter Radiation Regimens Among US Patients With
Prostate Cancer: A Focus on Asian American and Pacific Islander Patients.
Prostate. 2025 Mar 31. doi: 10.1002/pros.24887. PubMedAbstract available
VASSALLO R, Mannas MP, Salcudean SE, Black PC, et al Developments in Ultrasound-Based Imaging for Prostate Cancer Detection.
Prostate. 2025 Mar 28. doi: 10.1002/pros.24893. PubMedAbstract available
LOSEE M, Kavanaugh M, Liu M, Borges N, et al Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for
Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center
Experience.
Prostate. 2025 Mar 18. doi: 10.1002/pros.24880. PubMedAbstract available
NG K, Priyadarshini G, Sarker SJ, Robinson A, et al A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for
Castrate-Resistant Prostate Cancer (TRICREST).
Prostate. 2025 Mar 18:e24877. doi: 10.1002/pros.24877. PubMedAbstract available
SUZUKI K, Hirata J, Okamura Y, Bando Y, et al Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of >/= 80 Years
of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World
Multi-Intuitional Analysis.
Prostate. 2025 Mar 16. doi: 10.1002/pros.24889. PubMedAbstract available
MONDIA MWL, Batchala PP, Dreicer R, Devitt ME, et al Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and
MRI: A Case Series and Literature Review.
Prostate. 2025 Mar 13. doi: 10.1002/pros.24890. PubMedAbstract available
ONAL C, Guler OC, Erbay G, Demirhan B, et al Propensity Score Matched Analysis of External Beam Radiotherapy With or Without
Focal Boost to Intraprostatic Lesions in Prostate Cancer.
Prostate. 2025 Mar 11. doi: 10.1002/pros.24888. PubMedAbstract available
VIGANO S, Finati M, Stephens A, Bertini A, et al Socioeconomic Disparities in Prostate Cancer Treatment: The Impact of Area
Deprivation Index on Initial Treatment Type for Localized PCa in a North-American
Cohort.
Prostate. 2025 Mar 11:e24882. doi: 10.1002/pros.24882. PubMedAbstract available
CHEN G, Li Y, Geng S, Lv L, et al Evaluating the Heterogeneity of Advanced Prostate Cancer by (18)F-DCFPyL and
(18)F-FDG PET/CT in a Prospective Cohort.
Prostate. 2025 Mar 5. doi: 10.1002/pros.24881. PubMedAbstract available
SHI Y, Wei X, Zhao F, Chen J, et al The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in
Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate.
Prostate. 2025 Mar 4:e24869. doi: 10.1002/pros.24869. PubMedAbstract available
ROBINSON E, Kinsella N, Ap Dafydd D, Shur J, et al Prostate Specific Antigen Density and Clinically-Significant Prostate Cancer: The
Influence of Prostatic Volume.
Prostate. 2025 Mar 3. doi: 10.1002/pros.24886. PubMedAbstract available
ORSINI A, Ferretti S, Porreca A, Castellan P, et al PI-RADS in Predicting csPCa: A Comparison Between Academic and Nonacademic
Centers.
Prostate. 2025;85:337-343. PubMedAbstract available
AYRANCI A, Caglar U, Yazili HB, Erdal FS, et al PSA Density and Lesion Volume: Key Factors in Avoiding Unnecessary Biopsies for
PI-RADS 3 Lesions.
Prostate. 2025;85:385-390. PubMedAbstract available
ODERDA M, Marquis A, Bertero L, Calleris G, et al Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of
Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis.
Prostate. 2025;85:374-384. PubMedAbstract available
February 2025
CHEN H, Pang B, Liu Z, Li B, et al The Diagnostic Value of Plasma Small Extracellular Vesicle-Derived CAIX Protein
in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on
Predictive Models.
Prostate. 2025 Feb 27. doi: 10.1002/pros.24879. PubMedAbstract available
ESEN B, Seymen H, Armutlu A, Koseoglu E, et al Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in
Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET.
Prostate. 2025 Feb 27:e24884. doi: 10.1002/pros.24884. PubMedAbstract available
ESENGUR OT, Stevenson E, Stecko H, Lay NS, et al Assessing the Impact of Transition and Peripheral Zone PSA Densities Over
Whole-Gland PSA Density for Prostate Cancer Detection on Multiparametric MRI.
Prostate. 2025 Feb 25:e24863. doi: 10.1002/pros.24863. PubMedAbstract available
HUNT TC, Cheng Z, Li A, Pamatmat AJ, et al The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate
Cancer.
Prostate. 2025 Feb 24:e24870. doi: 10.1002/pros.24870. PubMedAbstract available
TILKI B, Hurmuz P, Yuce D, Ozyigit G, et al Translation, Cross-Cultural Adaptation, and Psychometric Validation of the
Turkish Version of the "Expanded Prostate Cancer Index Composite (EPIC)" in
Prostate Cancer Patients.
Prostate. 2025 Feb 23:e24878. doi: 10.1002/pros.24878. PubMedAbstract available
RETRACTION: Stat3 Enhances the Growth of LNCaP Human Prostate Cancer Cells in
Intact and Castrated Male Nude Mice.
Prostate. 2025 Feb 21:e24872. doi: 10.1002/pros.24872. PubMed
BRITTON CJ, Andrews JR, Arafa A, Kim Y, et al Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically
Significant Prostate Cancer: A Prospective Single-Institution Pilot Study.
Prostate. 2025 Feb 20:e24861. doi: 10.1002/pros.24861. PubMedAbstract available
HACIOGLU MB, Kucukarda A, Gokmen I, Gurbuz AF, et al Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive
Prostate Cancer: Impact on Survival and Treatment Optimization.
Prostate. 2025 Feb 19. doi: 10.1002/pros.24876. PubMedAbstract available
KAMBE T, Kubota M, Yamasaki T, Kawakita M, et al Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low-Dose
Estramustine in Very High-Risk Prostate Cancer Undergoing Robotic Radical
Prostatectomy.
Prostate. 2025 Feb 19:e24875. doi: 10.1002/pros.24875. PubMedAbstract available
HABAULT J, Franco JL, Ha S, Schneider JA, et al In Vivo Efficacy of a Macrocyclic Peptoid-Peptide Hybrid That Selectively
Modulates the Beta-Catenin/TCF Interaction to Inhibit Prostate Cancer.
Prostate. 2025 Feb 16:e24868. doi: 10.1002/pros.24868. PubMedAbstract available
KAVAK EE, Dilli I Progression-Free Survival Prediction Performance of ChatGPT: Analysis With Real
Life Data in Early and Locally Advanced Prostate Cancer.
Prostate. 2025 Feb 13:e24871. doi: 10.1002/pros.24871. PubMedAbstract available
DIAMAND R, Bernard PL, Mjaess G, Benijts J, et al Retzius-sparing versus standard robot-assisted laparoscopic prostatectomy: A
two-year patient-reported and oncological assessment.
Prostate. 2025;85:115-122. PubMedAbstract available
CHAI H, Miyasaka Y, Hagiwara Y, Souda H, et al Investigation of pelvic floor influence on prostate displacement in image-guided
radiotherapy.
Prostate. 2025;85:123-129. PubMedAbstract available
YANAI Y, Kosaka T, Mikami S, Arai M, et al Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation
Therapy.
Prostate. 2025;85:308-314. PubMedAbstract available
January 2025
NISHIMOTO M, De Velasco MA, Yamamoto Y, Fujimoto S, et al Immunohistochemical Analysis of Androgen Receptor Expression Predicts the
Prognosis of Metastatic Castration-Sensitive Prostate Cancer Patients Receiving
Abiraterone Acetate.
Prostate. 2025 Jan 31:e24865. doi: 10.1002/pros.24865. PubMedAbstract available
SUN Y, Zhu J, Zhong H, Zhang Z, et al Transcriptome-Wide Association Study Identified Novel Blood Tissue Gene
Biomarkers for Prostate Cancer Risk.
Prostate. 2025 Jan 29:e24859. doi: 10.1002/pros.24859. PubMedAbstract available
SHEN C, Chen Z, Hu FH, Wang W, et al Reassessing the Role of Low PSA in Prognosis Across Grades of Prostate Cancer: A
Cohort Study.
Prostate. 2025 Jan 29:e24860. doi: 10.1002/pros.24860. PubMedAbstract available
BEATRICI E, De Carne F, Frego N, Moretto S, et al Optimizing Prostate Cancer Diagnostic Work-Up Through Micro-Ultrasound:
Minimizing Unnecessary Procedures and Reducing Overdiagnoses.
Prostate. 2025 Jan 28:e24862. doi: 10.1002/pros.24862. PubMedAbstract available
CIRULLI GO, Stephens A, Chiarelli G, Finati M, et al Comparing PSA Screening Patterns and Their Role as Predictor of Prostate Cancer
Diagnosis: Analysis of a Contemporary North American Cohort.
Prostate. 2025 Jan 27:e24856. doi: 10.1002/pros.24856. PubMedAbstract available
BESIROGLU H, Kadihasanoglu M The Safety and Efficacy of Targeted Alpha Therapy, Ac-225 Prostate-Specific
Membrane Antigen, in Patients With Metastatic Castration-Resistant Prostate
Cancer: A Systematic Review and Meta-Analysis.
Prostate. 2025 Jan 26:e24857. doi: 10.1002/pros.24857. PubMedAbstract available
STANGL-KREMSER J, Ricaurte-Fajardo A, Huicochea Castellanos S, Martinez-Fundichely A, et al Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in
Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis.
Prostate. 2025 Jan 23:e24853. doi: 10.1002/pros.24853. PubMedAbstract available
UEDA T, Hayakawa K, Horiguchi G, Murashita J, et al Screening for Predictive Factors of Efficacy of Second-Generation Androgen
Receptor Axis-Targeted Agents in Patients With High-Risk Metastatic
Hormone-Sensitive Prostate Cancer.
Prostate. 2025 Jan 15:e24855. doi: 10.1002/pros.24855. PubMedAbstract available
BELKACEMI Y, Coraggio G, Debbi K, Sirmai L, et al Relationship Between Radiation Therapy and Fecal Incontinence in Patients Treated
for Localized Prostate Cancer: Results of the French ICONES Study.
Prostate. 2025 Jan 14:e24852. doi: 10.1002/pros.24852. PubMedAbstract available
BAHRI RA, Mohammadi A, Yar EZ, Rezayat M, et al Does a Negative Prostate Biopsy Reduce the Risk of Prostate Cancer
Reclassification in an Active Surveillance Protocol? An Updated Systematic Review
and Meta-Analysis.
Prostate. 2025 Jan 12:e24851. doi: 10.1002/pros.24851. PubMedAbstract available
KATO H, Goto Y, Kojima S, Onoda Y, et al Time to Castration Resistance is Associated With Overall Survival Even After the
Achievement of Castration Resistance in Metastatic Prostate Cancer.
Prostate. 2025 Jan 7:e24850. doi: 10.1002/pros.24850. PubMedAbstract available
ANJALY K, Tiku AB Exogenous Treatment of Caffeic Acid and Methylglyoxal Synergistically Enhances
Anticancer Effect in Prostate Cancer via Inhibition of Glyoxalase-1.
Prostate. 2025 Jan 2. doi: 10.1002/pros.24849. PubMedAbstract available
TANG CY, Li JJX, Leung KL, Ma HY, et al Is prostatic adenocarcinoma detectable by urine cytology-A multicenter
retrospective review.
Prostate. 2025;85:97-104. PubMedAbstract available
December 2024
SUZUKI K, Hara T, Watanabe H, Nakane K, et al Rapid and Deep Prostate-Specific Antigen Decline is a Prognostic Marker in
Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Multi-Intuitional
Analysis.
Prostate. 2024 Dec 27. doi: 10.1002/pros.24847. PubMedAbstract available
BARONE B, Amicuzi U, Massanova M, Napolitano L, et al The Correlation Between Body Mass Index and Prostate Volume: A Retrospective
Analysis of Pre and Postoperative Measurements in Prostate Cancer Patients.
Prostate. 2024 Dec 23. doi: 10.1002/pros.24845. PubMedAbstract available
ABER ER, Carducci MA, Paller CJ, Denmeade SR, et al Association of SGLT2 Inhibitor Initiation and PSA Response in Prostate Cancer.
Prostate. 2024 Dec 22. doi: 10.1002/pros.24841. PubMedAbstract available
YORIOKA MAW, Murta CB, Leite KRM, Cardili L, et al ERG and PTEN Role on Active Surveillance for Low-Risk Prostate Cancer in the
Multiparametric MRI Era.
Prostate. 2024 Dec 9:e24835. doi: 10.1002/pros.24835. PubMedAbstract available
CHIARELLI G, Davis M, Stephens A, Finati M, et al Racial Disparities in Future Development of Lethal Prostate Cancer Based on
Midlife Baseline Prostate-Specific Antigen.
Prostate. 2024 Dec 9:e24834. doi: 10.1002/pros.24834. PubMedAbstract available
IWAHASHI Y, Wakamiya T, Kawabata H, Deguchi R, et al Comparison of Prognosis and Health-Related Quality of Life Between Robot-Assisted
Radical Prostatectomy Versus High-Dose-Rate Brachytherapy Combined With External
Beam Radiation Therapy and Hormone Therapy for High-Risk Prostate Cancer.
Prostate. 2024 Dec 5. doi: 10.1002/pros.24831. PubMedAbstract available
OLDAN JD, Rowe SP, Schroeder JA Evaluation of online teaching modules for PSMA PET interpretation.
Prostate. 2024;84:1419-1426. PubMedAbstract available
ONAL C, Elmali A, Erbay G, Demirhan B, et al Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive
Radiotherapy for Gleason Score 7 Prostate Cancer Patients.
Prostate. 2024 Dec 1. doi: 10.1002/pros.24833. PubMedAbstract available
MIYAHIRA AK, Soule HR, Pienta KJ CHARGE: The "Big Questions" in Prostate Cancer for 2024.
Prostate. 2024 Dec 1. doi: 10.1002/pros.24829. PubMed
November 2024
MIYAHIRA AK, Sharifi M, Chesner LN, El-Kenawi A, et al Personalized Medicine: Leave no Patient Behind; Report From the 2024
Coffey-Holden Prostate Cancer Academy Meeting.
Prostate. 2024 Nov 27. doi: 10.1002/pros.24826. PubMedAbstract available
HE E, Li Y, Zhao R, Kong Q, et al IL7 as a Risk Factor for Prostate Cancer: Implications for T Cell Apoptosis and
Infiltration in the Tumor Microenvironment.
Prostate. 2024 Nov 26. doi: 10.1002/pros.24830. PubMedAbstract available
GLADIS PUSHPARATHI VP, Justin Xavier D, Chitra P, Kannan G, et al Prostate Cancer Classification and Interpretation With Multiparametric Magnetic
Resonance Imaging and Gleason Grade Score Using DarkNet53 Model.
Prostate. 2024 Nov 25:e24827. doi: 10.1002/pros.24827. PubMedAbstract available
NAGASAKA H, Sato S, Suzuki A, Terao H, et al Clinicopathological Significance of Extranodal Adipose Tissue Invasion in
Metastatic Lymph Nodes in Patients With Prostate Cancer.
Prostate. 2024 Nov 20. doi: 10.1002/pros.24825. PubMedAbstract available
RETRACTION: Glyoxalase 2 Is Involved in Human Prostate Cancer Progression as Part
of a Mechanism Driven By PTEN/PI3K/AKT/mTOR Signaling With Involvement of PKM2
and ERalpha.
Prostate. 2024 Nov 17. doi: 10.1002/pros.24822. PubMed
JUNIOR EP, Gomes EFDA, de Lima MFR, Raimundo JVS, et al Reactive Stroma and Acinar Morphology in Prostate Cancer: Implications for
Progression and Prognostic Assessment.
Prostate. 2024 Nov 13. doi: 10.1002/pros.24824. PubMedAbstract available
BIALAS P, Kobayashi T, Hellsten R, Krzyzanowska A, et al pSTAT3 Expression is Increased in Advanced Prostate Cancer in Post-Initiation of
Androgen Deprivation Therapy.
Prostate. 2024 Nov 11. doi: 10.1002/pros.24820. PubMedAbstract available
TAKAHASHI T, Nakashima M, Maruno K, Hazama T, et al Comparative Evaluation of Detection Rates for Clinically Significant Prostate
Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic
Biopsies: Development of a Risk-Stratification Scoring System.
Prostate. 2024 Nov 10. doi: 10.1002/pros.24821. PubMedAbstract available
TAO H, Wu F, Li R, Du X, et al Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel
Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer.
Prostate. 2024 Nov 3. doi: 10.1002/pros.24817. PubMedAbstract available
ZHAO X, Sakamoto S, Ishikawa H, Yamada Y, et al Significant Effect of Carbon-Ion Radiation Therapy Combined With Androgen
Deprivation on Biochemical Recurrence Rates in High-Risk Prostate Cancer
Patients: A Two-Center Controlled Trial Compare With X-Ray External Beam
Radiation Therapy.
Prostate. 2024 Nov 3. doi: 10.1002/pros.24818. PubMedAbstract available
October 2024
WEI X, Zhao J, Nie L, Shi Y, et al Assessing the predictive value of intraductal carcinoma of the prostate (IDC-P)
in determining abiraterone efficacy for metastatic hormone-sensitive prostate
cancer (mHSPC) patients.
Prostate. 2024 Oct 28. doi: 10.1002/pros.24809. PubMedAbstract available
FINATI M, Morrison C, Stephens A, Chiarelli G, et al Association of race with incidence, characteristics, and mortality from
incidental prostate cancer: Analysis of two North American contemporary cohorts.
Prostate. 2024 Oct 28:e24803. doi: 10.1002/pros.24803. PubMedAbstract available
WHYNE EZ, Jeon-Slaughter H, Kelly K, Dowell JE, et al Effects of Concurrent Administration of Spironolactone in Veterans with
Metastatic Prostate Cancer Receiving Abiraterone: A Real-World Retrospective
Study.
Prostate. 2024 Oct 28. doi: 10.1002/pros.24811. PubMedAbstract available
DI BELLO F, Jannello LMI, Baudo A, de Angelis M, et al Life Expectancy in High-Grade Incidental Prostate Cancer Patients Versus
Population-Based Controls According to Treatment Type.
Prostate. 2024 Oct 24:e24816. doi: 10.1002/pros.24816. PubMedAbstract available
ERTL IE, Lemberger U, Rajwa P, Petrov P, et al Low SMARCD3 expression is associated with poor prognosis in patients with
prostate cancer.
Prostate. 2024 Oct 23. doi: 10.1002/pros.24815. PubMedAbstract available
SHUKLA S, Osumi T, Al-Toubat M, Serrano S, et al Protein kinase D1 mitigation against etoposide induced DNA damage in prostate
cancer is associated with increased alpha-Catenin.
Prostate. 2024 Oct 20. doi: 10.1002/pros.24812. PubMedAbstract available
YANAGISAWA T, Fukuokaya W, Hatakeyama S, Narita S, et al Comparison of abiraterone, enzalutamide, and apalutamide for metastatic
hormone-sensitive prostate cancer: A multicenter study.
Prostate. 2024 Oct 17:e24813. doi: 10.1002/pros.24813. PubMedAbstract available
SEMWAL H, Ladbury C, Sabbagh A, Mohamad O, et al Machine learning and explainable artificial intelligence to predict pathologic
stage in men with localized prostate cancer.
Prostate. 2024 Oct 13. doi: 10.1002/pros.24793. PubMedAbstract available
FALKENBACH F, Schmalhofer ML, Tian Z, Mazzucato G, et al Size and SUV(max) define the contribution of nodal metastases to PSA in
oligorecurrent prostate cancer.
Prostate. 2024 Oct 9. doi: 10.1002/pros.24806. PubMedAbstract available
TSAI K, Xu P, Guo J, Dean N, et al Do Prostate Imaging-Reporting and Data System (PIRADS) lesions predict holmium
laser enucleation of prostate outcomes?
Prostate. 2024;84:1344-1351. PubMedAbstract available
September 2024
DINCKAL M, Ergun KE, Kalemci MS, Guler E, et al Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings
with postoperative results in preoperative locoregional staging and localization
of prostate cancer.
Prostate. 2024 Sep 30. doi: 10.1002/pros.24799. PubMedAbstract available
NARITA S, Yanagisawa T, Hatakeyama S, Hata K, et al Prognostic model for second progression-free survival and overall survival in
patients with high-risk metastatic hormone-sensitive prostate cancer treated with
abiraterone acetate and androgen deprivation therapy.
Prostate. 2024 Sep 30. doi: 10.1002/pros.24802. PubMedAbstract available
YAZGAN SC, Yekeduz E, Araz M, Bolek H, et al The prognostic role of pan-immune inflammation value in patients with metastatic
castration resistance prostate cancer treated with Lutetium-177
((177)Lu)-PSMA-617.
Prostate. 2024 Sep 29. doi: 10.1002/pros.24804. PubMedAbstract available
JIRASKO M, Vitak R, Pecen L, Pinkeova A, et al Serum levels of prostate specific antigen, free PSA, [-2]proPSA, fPSA/tPSA ratio,
Prostate Health Index, and glycosylation patterns of free PSA in patients with
benign prostatic hyperplasia pharmacotherapy.
Prostate. 2024 Sep 27. doi: 10.1002/pros.24801. PubMedAbstract available
MURTA CB, Junior JP, de Souza Filho PHF, de Godoy Junior PC, et al Prostate cancer focal therapy: surgeon experience influences oncological results.
Prostate. 2024 Sep 26. doi: 10.1002/pros.24800. PubMedAbstract available
TRAN EU, Ovruchesky E, Yamamoto K, Marley S, et al Bipolar androgen therapy for treatment of metastatic castration-resistant
prostate cancer: A case series.
Prostate. 2024 Sep 22. doi: 10.1002/pros.24798. PubMedAbstract available
TANAKA N, Izumi K, Nakai Y, Shima T, et al Dose modification in enzalutamide and abiraterone plus prednisolone for
castration-resistant prostate cancer: A subanalysis from the ENABLE study for
PCa.
Prostate. 2024 Sep 20. doi: 10.1002/pros.24796. PubMedAbstract available
WONG CH, Ko IC, Leung DK, Siu B, et al Deep PSA response and extended time-to-nadir as robust predictors of survival in
Asian patients with de novo metastatic hormone-sensitive prostate cancer
receiving upfront intensified treatment.
Prostate. 2024 Sep 19. doi: 10.1002/pros.24797. PubMedAbstract available
DE JESUS GNC, Pereira V, Karak P, Shearier E, et al A single-center retrospective review of metastatic prostate cancer on PSMA
position emission tomography/computed tomography: Beyond lymph nodes and bones.
Prostate. 2024 Sep 18. doi: 10.1002/pros.24795. PubMedAbstract available
UEKI H, Jimbo N, Terakawa T, Hara T, et al Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine
prostate cancer through immunohistochemistry and genomic analysis of RB1 and
TP53.
Prostate. 2024 Sep 15. doi: 10.1002/pros.24791. PubMedAbstract available
KATO T, Sugihara E, Hata Y, Kawakami K, et al Diagnostic potential of SDHB mRNA contained in serum extracellular vesicles among
patients with prostate cancer.
Prostate. 2024 Sep 15. doi: 10.1002/pros.24792. PubMedAbstract available
LIU X, Zhu J, Shi MQ, Pan YS, et al Predicting clinically significant prostate cancer in elderly patients: A nomogram
approach with shear wave elastography.
Prostate. 2024 Sep 12. doi: 10.1002/pros.24789. PubMedAbstract available
BOIARSKY D, Tewari AK, Gulhan DC, Bakouny Z, et al A panel-based mutational signature of homologous recombination deficiency
associates with response to PARP inhibition in metastatic castration-resistant
prostate cancer.
Prostate. 2024 Sep 9. doi: 10.1002/pros.24788. PubMedAbstract available
MATRONE F, Del Ben F, Montico M, Muraro E, et al Prognostic value of circulating tumor cells in oligorecurrent hormone-sensitive
prostate cancer patients undergoing stereotactic body radiation therapy.
Prostate. 2024 Sep 6. doi: 10.1002/pros.24787. PubMedAbstract available
HIMMELSBACH R, Hacklander A, Weishaar M, Morlock J, et al Retrospective analysis of the learning curve in perineal robot-assisted prostate
biopsy.
Prostate. 2024;84:1165-1172. PubMedAbstract available
OZKAYA M, Simsekoglu MF, Kalender G, Sahin KC, et al Clinical and histopathological parameters in transrectal ultrasound-guided
biopsies associated with tumor upgrading after radical prostatectomy: A
comparative analysis of risk groups.
Prostate. 2024;84:1146-1156. PubMedAbstract available
BARRIERE H, Kaulanjan K, Stempfer G, Mollard P, et al Overall and metastasis-free survival of Afro-Caribbean patients with biochemical
recurrence after radical prostatectomy.
Prostate. 2024;84:1112-1118. PubMedAbstract available
WEI Y, Wang H, Xie D, Lu J, et al Analysis of three primary prostatic sarcoma cases and literature review.
Prostate. 2024;84:1218-1223. PubMedAbstract available
CHEN VS, James C, Khemmani M, Desai S, et al A prospective evaluation of the prostate microbiome in malignant and benign
tissue using transperineal biopsy.
Prostate. 2024;84:1251-1261. PubMedAbstract available
ADAMS ES, Deivasigamani S, Kotamarti S, Wolf S, et al Image-guided multiparametric magnetic resonance imaging-transrectal ultrasound
fusion biopsy augmented with a sextant versus an extended template random biopsy:
Comparison of cancer detection rates, complication and functional outcomes.
Prostate. 2024;84:1224-1233. PubMedAbstract available
MADENDERE S, Kilic M, Zoroglu H, Sarikaya AF, et al Natural history of histologically benign PIRADS 4-5 lesions in multiparametric
MRI: Real-life experience in an academic center.
Prostate. 2024;84:1262-1267. PubMedAbstract available
FALKENBACH F, Ahmad-Sterkau F, Kachanov M, Beyersdorff D, et al Bimodal imaging: Detection rate of clinically significant prostate cancer is
higher in MRI lesions visible to transrectal ultrasound.
Prostate. 2024 Sep 1. doi: 10.1002/pros.24785. PubMedAbstract available
LU S, Lamba M, Wang J, Dong Z, et al Targeting proliferating cell nuclear antigen enhances ionizing radiation-induced
cytotoxicity in prostate cancer cells.
Prostate. 2024 Sep 1. doi: 10.1002/pros.24786. PubMedAbstract available
August 2024
TANEGASHIMA T, Shiota M, Eto M Reply to Letter to the Editor on "Impact of proton pump inhibitors on the
efficacy of androgen receptor signaling inhibitors in metastatic
castration-resistant prostate cancer patients".
Prostate. 2024 Aug 21. doi: 10.1002/pros.24784. PubMed
WANG J, Lao Y, Guan X, Li Z, et al Incidence and risk factors of prostate cancer among the Northern and Eastern
parts of the United Arab Emirates population.
Prostate. 2024 Aug 21. doi: 10.1002/pros.24671. PubMed
SAHEB SHARIF-ASKARI F, Al-Shahrabi R, Al Shareef Z Response to the letter to the editor: Incidence and risk factors of prostate
cancer among the Northern and Eastern parts of the United Arab Emirates
population.
Prostate. 2024 Aug 21. doi: 10.1002/pros.24779. PubMed
SWAMI U, Xie B, Young C, Ramaswamy K, et al Real-world prevalence of adverse events with first-line systemic therapies among
patients with metastatic castration-sensitive prostate cancer.
Prostate. 2024 Aug 20. doi: 10.1002/pros.24777. PubMedAbstract available
LI EV, Lee MS, Guo J, Dean N, et al Modern predictors and management of incidental prostate cancer at holmium
enucleation of prostate.
Prostate. 2024 Aug 18. doi: 10.1002/pros.24781. PubMedAbstract available
HSIEH CL, Do AD, Hsueh CY, Raboshakga MO, et al L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells.
Prostate. 2024 Aug 18. doi: 10.1002/pros.24782. PubMedAbstract available
LIU T, Joshu CE, Lu J, Prizment A, et al Validation of candidate protein biomarkers previously identified by genetic
instruments for prostate cancer risk: A prospective cohort analysis of directly
measured protein levels in the ARIC study.
Prostate. 2024 Aug 15. doi: 10.1002/pros.24774. PubMedAbstract available
WANG H, He K, Liu Y, Yang L, et al Expression and immune infiltration studies of IL-33-ST2-NF-kappaB signaling pathway
in prostate cancer.
Prostate. 2024 Aug 7. doi: 10.1002/pros.24778. PubMedAbstract available
WAKAMORI C, De Velasco MA, Sakai K, Kura Y, et al A cross-species analysis of fecal microbiomes in humans and mice reveals
similarities and dissimilarities associated with prostate cancer risk.
Prostate. 2024 Aug 7. doi: 10.1002/pros.24776. PubMedAbstract available
ONAL C, Guler OC, Torun N, Elmali A, et al Impact of definitive radiotherapy on metabolic response measured with
(68)Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer.
Prostate. 2024 Aug 6. doi: 10.1002/pros.24775. PubMedAbstract available
GREENLAND NY, Cooperberg MR, Carroll PR, Cowan JE, et al Morphologic patterns observed in prostate biopsy cases with discrepant grade
group and molecular risk classification.
Prostate. 2024;84:1076-1085. PubMedAbstract available
PETERS DE, Brownlee M, Layne-Colon D, Slusher BS, et al Discovery of PSMA in the prostate of the common marmoset (Callithrix jacchus).
Prostate. 2024;84:1086-1088. PubMedAbstract available
July 2024
SCHMIT S, Malshy K, Ochsner A, Golijanin B, et al Lower urinary tract symptoms in elderly men: Considerations for prostate cancer
testing.
Prostate. 2024 Jul 25. doi: 10.1002/pros.24772. PubMedAbstract available
FRIEDRICH NA, Gu L, Waller J, De Hoedt AM, et al Real-world evidence of (18)F-fluciclovine Positron emission tomography/computed
tomography performance for recurrent prostate cancer in the Veterans Affairs
Health System.
Prostate. 2024 Jul 19. doi: 10.1002/pros.24770. PubMedAbstract available
MIYAHIRA AK, Soule HR The 30th Annual Prostate Cancer Foundation Scientific Retreat Report.
Prostate. 2024 Jul 17. doi: 10.1002/pros.24768. PubMedAbstract available
SUTERA P, Kim J, Kumar R, Deek RA, et al PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate
cancer.
Prostate. 2024 Jul 17. doi: 10.1002/pros.24765. PubMedAbstract available
TANEGASHIMA T, Shiota M, Tsukahara S, Mutaguch J, et al Impact of proton pump inhibitors on the efficacy of androgen receptor signaling
inhibitors in metastatic castration-resistant prostate cancer patients.
Prostate. 2024 Jul 10. doi: 10.1002/pros.24769. PubMedAbstract available
WENZEL M, Wagner N, Hoeh B, Siech C, et al Survival of patients with lymph node versus bone versus visceral metastases
according to CHAARTED/LATITUDE criteria in the era of intensified combination
therapies for metastatic hormone-sensitive prostate cancer.
Prostate. 2024 Jul 10. doi: 10.1002/pros.24767. PubMedAbstract available
JASMINE S, Mandl A, Krueger TEG, Dalrymple SL, et al Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic
properties of the LSD1 inhibitor bomedemstat in preclinical models.
Prostate. 2024;84:909-921. PubMedAbstract available
June 2024
KAYAR R, Tokuc E, Ozsoy E, Demir S, et al The predictive impact of hematological inflammatory markers in detecting prostate
cancer in patients with PI-RADS 3 lesions on multiparametric magnetic resonance
imaging.
Prostate. 2024 Jun 26. doi: 10.1002/pros.24762. PubMedAbstract available
MASSANOVA M, Barone B, Caputo VF, Napolitano L, et al The detection rate for prostate cancer in systematic and targeted prostate biopsy
in biopsy-naive patients, according to the localization of the lesion at the
mpMRI: A single-center retrospective observational study.
Prostate. 2024 Jun 25. doi: 10.1002/pros.24761. PubMedAbstract available
PRAKASH P, Verma S, Gupta S Influence of microbiome in intraprostatic inflammation and prostate cancer.
Prostate. 2024 Jun 20. doi: 10.1002/pros.24756. PubMedAbstract available
MALSHY K, Ochsner A, Homer A, Allu S, et al Consistent predictive ability of prostate-specific antigen density prediction
model for clinically significant prostate cancer across age strata.
Prostate. 2024 Jun 20. doi: 10.1002/pros.24757. PubMedAbstract available
CORDOBA SANCHEZ J, Monge-Escartin I, Gil J, Carrera C, et al Real-world study: Impact of multidisciplinary management of
apalutamide-associated adverse events in prostate cancer.
Prostate. 2024 Jun 18. doi: 10.1002/pros.24755. PubMedAbstract available
ABRAMOVIC I, Pezelj I, Dumbovic L, Skara Abramovic L, et al LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker
outperforming PSA.
Prostate. 2024 Jun 2. doi: 10.1002/pros.24749. PubMedAbstract available
DONG Q, Wang C, Shen D, Ma Y, et al Combination of prostate volume and apparent diffusion coefficient can stratify
patients with a PI-RADS score of 3 to reduce unnecessary prostate biopsies.
Prostate. 2024;84:780-787. PubMedAbstract available
BUTTNER T, Gartner F, Essler M, Weiten R, et al Key learnings from concordant systematic biopsies in prostate-specific membrane
antigen positron emission tomography/computed tomography-guided prostate
biopsies: Enhancing targeting accuracy.
Prostate. 2024;84:772-779. PubMedAbstract available
FLETCHER SA, Mamawala MM, Holler AE, Bhanji Y, et al Cumulative cancer locations on prostate biopsy and active surveillance outcomes
in the MRI era.
Prostate. 2024;84:723-730. PubMedAbstract available
BENNETT R 4TH, Li EV, Ho AY, Aguiar JA, et al Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use
criteria in a large network system.
Prostate. 2024;84:717-722. PubMedAbstract available
CHECCUCCI E, De Cillis S, Alladio E, Piramide F, et al Ten-year functional and oncological outcomes of a prospective randomized
controlled trial comparing laparoscopic versus robot-assisted radical
prostatectomy.
Prostate. 2024;84:832-841. PubMedAbstract available
May 2024
WENZEL M, Hoeh B, Hurst F, Koll F, et al Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in
real-world setting of metastatic hormone-sensitive prostate cancer patients.
Prostate. 2024 May 29. doi: 10.1002/pros.24754. PubMedAbstract available
TOUMA N, Larose M, Ouellet J, Bedard-Tremblay D, et al External validation of the Memorial Sloan Kettering Cancer Center preoperative
nomogram predicting lymph node invasion in a cohort of high-grade prostate cancer
patients.
Prostate. 2024 May 27. doi: 10.1002/pros.24742. PubMedAbstract available
TIRUYE T, Roder D, FitzGerald LM, O'Callaghan M, et al Impact of comorbidities on prostate cancer-specific mortality: A population-based
cohort study.
Prostate. 2024 May 26. doi: 10.1002/pros.24750. PubMedAbstract available
FERRO M, Crocetto F, La Civita E, Fiorenza M, et al Serum (-2)proPSA/freePSAratio, (-2)proPSA/freePSA density, prostate health index,
and prostate health index density as clues to reveal postoperative clinically
significant prostate cancer in men with prostate-specific antigen 2-10 ng/mL.
Prostate. 2024 May 26. doi: 10.1002/pros.24752. PubMedAbstract available
ABEDALI Z, Woloshuk A, Cary C, Boris RS, et al Does larger prostate size provide protection for cancer specific outcomes in
localized prostate cancer.
Prostate. 2024 May 16. doi: 10.1002/pros.24743. PubMedAbstract available
BUTTNER T, Klumper N, Weiten R, Lossin P, et al Bellmunt risk score as a survival predictor in patients with metastatic
castration-resistant prostate cancer.
Prostate. 2024 May 15. doi: 10.1002/pros.24747. PubMedAbstract available
NAKAI Y, Tanaka N, Asakawa I, Ohnishi K, et al Efficacy of a hydrogel spacer for improving quality of life in patients with
prostate cancer undergoing low-dose-rate brachytherapy alone or in combination
with intensity-modulated radiotherapy: An observational study using propensity
score matching.
Prostate. 2024 May 12. doi: 10.1002/pros.24744. PubMedAbstract available
MACKAY S, Oduor IO, Burch TC, Main BP, et al Increased alpha2,3-sialyl N-glycosylated prostate-specific membrane antigen (PSMA) in
post-DRE urine is associated with high grade group prostate cancer.
Prostate. 2024 May 12. doi: 10.1002/pros.24724. PubMedAbstract available
ASHIDA S, Kawada C, Tanaka H, Kurabayashi A, et al Cutibacterium acnes invades prostate epithelial cells to induce BRCAness as a
possible pathogen of prostate cancer.
Prostate. 2024 May 9. doi: 10.1002/pros.24723. PubMedAbstract available
YIN J, Daryanani A, Lu F, Ku AT, et al Reproducible preclinical models of androgen receptor driven human prostate cancer
bone metastasis.
Prostate. 2024 May 6. doi: 10.1002/pros.24718. PubMedAbstract available
HEETMAN JG, Paulino Pereira LJ, Kelder JC, Soeterik TFW, et al The additional value of (68)Ga-PSMA PET/CT SUVmax in predicting ISUP GG >/= 2 and
ISUP GG >/= 3 prostate cancer in biopsy.
Prostate. 2024 May 5. doi: 10.1002/pros.24716. PubMedAbstract available
QAZI SU, Altaf Z, Zafar M, Tariq MA, et al Development of depression in patients using androgen deprivation therapy: A
systemic review and meta-analysis.
Prostate. 2024;84:525-538. PubMedAbstract available
ROMANO L, Napolitano L, Crocetto F, Sciorio C, et al Prostate and gut: Any relationship? A narrative review on the available evidence
and putative mechanisms.
Prostate. 2024;84:513-524. PubMedAbstract available
BERG FM, Correia ETO, Abenojar EC, Basilion JP, et al Multispecies comparative prostate anatomy by imaging: Implications for
experimental models of prostatic disease.
Prostate. 2024;84:682-693. PubMedAbstract available
SIMANEK V, Vrzakova R, Vitak R, Jirasko M, et al Preanalytical stability of molecular forms of prostate-specific antigen in serum
samples (PSA, free PSA, [-2]proPSA) and their impact on fPSA/tPSA ratio and PHI.
Prostate. 2024;84:656-665. PubMedAbstract available
KOSTECKA LG, Mendez S, Li M, Khare P, et al Cancer cells employ lipid droplets to survive toxic stress.
Prostate. 2024;84:644-655. PubMedAbstract available
April 2024
KARSH L, Du S, He J, Waters D, et al Differences in real-world outcomes by risk classification for localized prostate
cancer patients after radiation therapy.
Prostate. 2024 Apr 29. doi: 10.1002/pros.24720. PubMedAbstract available
MIYAHIRA AK, Kamran SC, Jamaspishvili T, Marshall CH, et al Disrupting prostate cancer research: Challenge accepted; report from the 2023
Coffey-Holden Prostate Cancer Academy Meeting.
Prostate. 2024 Apr 29. doi: 10.1002/pros.24721. PubMedAbstract available
NGUYEN AM, Carter GC, Wilson LM, Canfield S, et al Real-world utilization, patient characteristics, and treatment patterns among men
with localized prostate cancer tested with the 17-gene genomic prostate score(R)
(GPS(TM)) assay.
Prostate. 2024 Apr 26. doi: 10.1002/pros.24709. PubMedAbstract available
CHARLTON PV, O'Reilly D, Philippou Y, Rao SR, et al Molecular analysis of archival diagnostic prostate cancer biopsies identifies
genomic similarities in cases with progression post-radiotherapy, and those with
de novo metastatic disease.
Prostate. 2024 Apr 23. doi: 10.1002/pros.24715. PubMedAbstract available
KAREGAR-NIAVOL R, Ghaffari F, Saravi A, Fotokian Z, et al Translation and validation of a lifestyle questionnaire related to prostate
cancer.
Prostate. 2024 Apr 21. doi: 10.1002/pros.24713. PubMedAbstract available
MARSHALL CH, Gondek LP, Daniels V, Lu C, et al Association of PARP inhibitor treatment on the prevalence and progression of
clonal hematopoiesis in patients with advanced prostate cancer.
Prostate. 2024 Apr 20. doi: 10.1002/pros.24712. PubMedAbstract available
JIA T, Liu C, Guo P, Xu Y, et al FOXA1 regulates ribosomal RNA transcription in prostate cancer.
Prostate. 2024 Apr 17. doi: 10.1002/pros.24714. PubMedAbstract available
ZHAO F, Zhao J, Wei X, Shi Y, et al Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker
of proliferation Ki67.
Prostate. 2024 Apr 17. doi: 10.1002/pros.24710. PubMedAbstract available
GRINDEDAL EM, Zucknick M, Stormorken A, Ronne E, et al Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with
Lynch syndrome.
Prostate. 2024 Apr 17. doi: 10.1002/pros.24711. PubMedAbstract available
CHAUDARY N, Wiljer E, Foltz W, Thapa P, et al An orthotopic prostate cancer model for new treatment development using syngeneic
or patient-derived tumors.
Prostate. 2024 Apr 12. doi: 10.1002/pros.24701. PubMedAbstract available
BROWN LK, Kanagasabai T, Li G, Celada SI, et al Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating
AKT signaling with induction of senescence and apoptosis.
Prostate. 2024 Apr 11. doi: 10.1002/pros.24706. PubMedAbstract available
MARTELIN N, De Witt B, Chen B, Eschwege P, et al Development and validation of an imageless machine-learning algorithm for the
initial screening of prostate cancer.
Prostate. 2024 Apr 4. doi: 10.1002/pros.24703. PubMedAbstract available
MODLIN IM, Kidd M, Drozdov IA, Boegemann M, et al Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in
whole blood.
Prostate. 2024 Apr 3. doi: 10.1002/pros.24704. PubMedAbstract available
ALANAZI G, Alsubaie N, Nabi G, Gillingwater TH, et al Distribution of neurovascular structures within the prostate gland and their
relationship to complications after radical prostatectomy.
Prostate. 2024;84:491-501. PubMedAbstract available
GEBRAEL G, Hage Chehade C, Sayegh N, Tripathi N, et al Natural course of metastatic castration-resistant prostate cancer in the era of
intensified androgen deprivation therapy in the hormone-sensitive setting.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24696. PubMedAbstract available
KIM J, Park S, Kim S, Ryu S, et al Enhancing the anticancer effect of androgen deprivation therapy by
monocarboxylate transporter 1 inhibitor in prostate cancer cells.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24700. PubMedAbstract available
KU HC, Cheng E, Cheng CF A body shape index (ABSI) but not body mass index (BMI) is associated with
prostate cancer-specific mortality: Evidence from the US NHANES database.
Prostate. 2024 Apr 1. doi: 10.1002/pros.24698. PubMedAbstract available
March 2024
SHAHAIT M, Hakansson AK, Daniel RE, Hosny K, et al Quantification and molecular correlates of tertiary lymphoid structures in
primary prostate cancer.
Prostate. 2024 Mar 27. doi: 10.1002/pros.24684. PubMedAbstract available
MAHON KL, Sutherland SI, Lin HM, Stockler MR, et al Clinical validation of circulating GDF15/MIC-1 as a marker of response to
docetaxel and survival in men with metastatic castration-resistant prostate
cancer.
Prostate. 2024 Mar 27. doi: 10.1002/pros.24691. PubMedAbstract available
DWINA Y, Zaid LSM, Saraswati M, Rachmadi L, et al CD44 and CD133 protein expression might serve as a prognostic factor for early
occurrence castration-resistant prostate cancer.
Prostate. 2024 Mar 25. doi: 10.1002/pros.24690. PubMedAbstract available
ONAL C, Guler OC, Erbay G, Elmali A, et al The effect of dose-escalation radiotherapy with simultaneous-integrated-boost on
the use of short-term androgen deprivation therapy in patients with intermediate
risk prostate cancer.
Prostate. 2024 Mar 25. doi: 10.1002/pros.24693. PubMedAbstract available
DI BELLO F, Baudo A, de Angelis M, Jannello LMI, et al Other-cause mortality in incidental prostate cancer.
Prostate. 2024 Mar 20. doi: 10.1002/pros.24689. PubMedAbstract available
HEERS H, Chwilka O, Huber J, Vogelmeier C, et al VOC-based detection of prostate cancer using an electronic nose and ion mobility
spectrometry: A novel urine-based approach.
Prostate. 2024 Mar 18. doi: 10.1002/pros.24692. PubMedAbstract available
GU J, Chery L, Gonzalez GMN, Huff C, et al A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in
African American men with suspected prostate cancer following PSA screening.
Prostate. 2024 Mar 13. doi: 10.1002/pros.24686. PubMedAbstract available
BRENNEN WN, Le Magnen C, Karkampouna S, Anselmino N, et al Defining the challenges and opportunities for using patient-derived models in
prostate cancer research.
Prostate. 2024 Mar 7. doi: 10.1002/pros.24682. PubMedAbstract available
HUANG H, Liu Z, Ma Y, Shao Y, et al Based on PI-RADS v2.1 combining PHI and ADC values to guide prostate biopsy in
patients with PSA 4-20 ng/mL.
Prostate. 2024;84:376-388. PubMedAbstract available
February 2024
KAMADA S, Sakamoto S, Kinoshita R, Zhao X, et al Testosterone bounce predicts favorable prognoses for prostate cancer patients
treated with degarelix.
Prostate. 2024 Feb 27. doi: 10.1002/pros.24679. PubMedAbstract available
YE PC, Leu WJ, Yeh TY, Hsu YT, et al A novel HDAC6 inhibitor interferes microtubule dynamics and spindle assembly
checkpoint and sensitizes cisplatin-induced apoptosis in castration-resistant
prostate cancer.
Prostate. 2024 Feb 20. doi: 10.1002/pros.24678. PubMedAbstract available
LUO LS, Huang J, Luan HH, Mubarik S, et al Estimating disparities of prostate cancer burden and its attributable risk
factors for males across the BRICS-plus, 1990-2019: A comparable study of key
nations with emerging economies.
Prostate. 2024 Feb 8. doi: 10.1002/pros.24673. PubMedAbstract available
ULYS A, Jankevicus F, Jievaltas M, Venckus R, et al Efficacy, tolerability, and safety of teverelix DP in patients with advanced
prostate cancer: A multicenter, open-label, phase 2 trial.
Prostate. 2024 Feb 4. doi: 10.1002/pros.24674. PubMedAbstract available
HOYOS JA, Londono DR, Hoyos AG, Reyes EC, et al Impact of presentation timing in metastatic hormone-sensitive prostate cancer:
Characterization of patients and identification of prognostic factors.
Prostate. 2024 Feb 4. doi: 10.1002/pros.24672. PubMedAbstract available
January 2024
PANACH-NAVARRETE J, Gonzalez-Marrachelli V, Morales-Tatay JM, Garcia-Morata F, et al Metabolic analysis using HR-MAS in prostate tissue for prostate cancer diagnosis.
Prostate. 2024 Jan 11. doi: 10.1002/pros.24670. PubMedAbstract available
WHITE JA, Kaninjing ET, Adeniji KA, Jibrin P, et al Whole-exome sequencing of Nigerian benign prostatic hyperplasia reveals increased
alterations in apoptotic pathways.
Prostate. 2024 Jan 8. doi: 10.1002/pros.24662. PubMedAbstract available
DE KOUCHKOVSKY I, Chan E, Schloss C, Poehlein C, et al Diagnosis and management of neuroendocrine prostate cancer.
Prostate. 2024 Jan 3. doi: 10.1002/pros.24664. PubMedAbstract available
ZHANG C, Tu X, Dai J, Zhang Z, et al Utilization trend of prebiopsy multiparametric magnetic resonance imaging and its
impact on prostate cancer detection: Real-world insights from a high-volume
center in southwest China.
Prostate. 2024 Jan 3. doi: 10.1002/pros.24669. PubMedAbstract available
OZAWA Y, Nohara S, Nakamura K, Hattori S, et al Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer
leads to biochemical recurrence after brachytherapy as monotherapy.
Prostate. 2024 Jan 3. doi: 10.1002/pros.24668. PubMedAbstract available
December 2023
MACKAY S, Oduor IO, Burch TC, Troyer DA, et al Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients
seminal plasma.
Prostate. 2023 Dec 27. doi: 10.1002/pros.24666. PubMedAbstract available
PELLEGRINO F, Stabile A, Sorce G, Mazzone E, et al Variability of mpMRI diagnostic performance according to the upfront individual
patient risk of having clinically significant prostate cancer.
Prostate. 2023 Dec 27. doi: 10.1002/pros.24665. PubMedAbstract available
XIE H, Chen J, Ma Z, Gao Y, et al PrLZ regulates EMT and invasion in prostate cancer via the TGF-beta1/p-smad2/miR-200
family/ZEB1 axis.
Prostate. 2023 Dec 25. doi: 10.1002/pros.24647. PubMedAbstract available
CANCEL M, Crottes D, Bellanger D, Bruyere F, et al Variable effects of periprostatic adipose tissue on prostate cancer cells: Role
of adipose tissue lipid composition and cancer cells related factors.
Prostate. 2023 Dec 19. doi: 10.1002/pros.24655. PubMedAbstract available
D'AGOSTINO GR, Badalamenti M, Stefanini S, Baldaccini D, et al Long term update on toxicity and survival of a phase II trial of linac-based
stereotactic body radiation therapy for low-intermediate risk prostate cancer.
Prostate. 2023 Dec 19. doi: 10.1002/pros.24657. PubMedAbstract available
LUKEZ A, Handorf E, Mendenhall NP, Henderson RH, et al A pooled patient-reported outcomes analysis of moderately hypofractionated proton
beam therapy and photon-based intensity modulated radiation therapy for low- or
intermediate-risk prostate cancer.
Prostate. 2023 Dec 18. doi: 10.1002/pros.24660. PubMedAbstract available
MOON D, Hauck JS, Jiang X, Quang H, et al Targeting glutamine dependence with DRP-104 inhibits proliferation and tumor
growth of castration-resistant prostate cancer.
Prostate. 2023 Dec 12. doi: 10.1002/pros.24654. PubMedAbstract available
ZENG J, Zhang Y, Xu R, Chen H, et al Nanomechanical-based classification of prostate tumor using atomic force
microscopy.
Prostate. 2023;83:1591-1601. PubMedAbstract available
BELUE MJ, Blake Z, Yilmaz EC, Lin Y, et al Is prostatic adenocarcinoma with cribriform architecture more difficult to detect
on prostate MRI?
Prostate. 2023;83:1519-1528. PubMedAbstract available
RAVI P, Kwak L, Devlies W, Xie W, et al Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical
prostatectomy for high-risk localized prostate cancer.
Prostate. 2023 Dec 1. doi: 10.1002/pros.24653. PubMedAbstract available
November 2023
AL SHAREEF Z, Al-Shahrabi R, Saheb Sharif-Askari F, AlDhmanie A, et al Incidence and risk factors of prostate cancer among the Northern and Eastern
parts of the United Arab Emirates population.
Prostate. 2023 Nov 15:e24637. doi: 10.1002/pros.24637. PubMedAbstract available
PALLER CJ, Barata PC, Lorentz J, Appleman LJ, et al PROMISE Registry: A prostate cancer registry of outcomes and germline mutations
for improved survival and treatment effectiveness.
Prostate. 2023 Nov 14. doi: 10.1002/pros.24650. PubMedAbstract available
MULLEN SA, Das D, Ziamiavaghi N, High R, et al Association of plasma NRP2 and VEGF-C levels with prostate cancer disease
severity.
Prostate. 2023 Nov 9. doi: 10.1002/pros.24648. PubMedAbstract available
LI J, Wang K, Li S, Wu P, et al Clinical study of multifactorial diagnosis in prostate biopsy.
Prostate. 2023;83:1494-1503. PubMedAbstract available
MIYAHIRA AK, Soule HR The 29th Annual Prostate Cancer Foundation Scientific Retreat Report.
Prostate. 2023 Nov 1:e24640. doi: 10.1002/pros.24640. PubMedAbstract available
GOVINDAN S, Cheranda N, Riekhof F, Luo S, et al Effect of BMI and hemoglobin A1c on survival of veterans with metastatic
castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Prostate. 2023 Nov 1. doi: 10.1002/pros.24644. PubMedAbstract available
October 2023
ALSAIDAN OA, Onobun E, Ye C, Lou L, et al Inhibition of N-myristoyltransferase activity promotes androgen receptor
degradation in prostate cancer.
Prostate. 2023 Oct 31. doi: 10.1002/pros.24645. PubMedAbstract available
DI H, Wen Y Vasectomy and risk of prostate cancer: A Mendelian randomization study and
confounder analysis.
Prostate. 2023 Oct 31. doi: 10.1002/pros.24646. PubMedAbstract available
FU W, Xu L, Chen Y, Zhang Z, et al Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear
translocation and increasing ferritinophagy.
Prostate. 2023 Oct 30. doi: 10.1002/pros.24642. PubMedAbstract available
MAHMOUD AM, Childs DS, Ahmed ME, Tuba Kendi A, et al Treatment modalities and survival outcomes in prostate cancer parenchymal brain
metastasis.
Prostate. 2023 Oct 29. doi: 10.1002/pros.24643. PubMedAbstract available
ECHEVERRIA CE, Oyarzun VI, Lopez-Cortes A, Cancino J, et al Biological role of fructose in the male reproductive system: Potential
implications for prostate cancer.
Prostate. 2023 Oct 27. doi: 10.1002/pros.24631. PubMedAbstract available
HU HP, Anagnostopoulos G, Gouran-Savadkoohi M, Dayes I, et al Disease control outcomes of stereotactic body radiation therapy or moderate
hypo-fractionation for prostate cancer: Real-world experience at two Canadian
centers.
Prostate. 2023 Oct 25. doi: 10.1002/pros.24638. PubMedAbstract available
MITCHELL AP, Persaud S, Palyca P, Salner A, et al Physician knowledge, practice patterns, and barriers encountered regarding
guideline-concordant use of bone modifying agents for prostate cancer.
Prostate. 2023 Oct 16. doi: 10.1002/pros.24636. PubMedAbstract available
SIEGELMANN-DANIELI N, Neiman V, Bareket-Samish A, Berger R, et al Whole exome germline sequencing in early-onset prostate cancer patients: Genomic
findings and clinical outcomes.
Prostate. 2023 Oct 16. doi: 10.1002/pros.24622. PubMedAbstract available
MENEZES RDS, Dornas MC, Campos CFF, Rodeiro DB, et al Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-ERG, and CTNNB1 polymorphisms
associated with prostate cancer in samples of patients from HUPE-UERJ.
Prostate. 2023 Oct 15. doi: 10.1002/pros.24635. PubMedAbstract available
PEDRAZA AM, Gupta R, Musheyev D, Pino T, et al Microultrasound in the detection of the index lesion in prostate cancer.
Prostate. 2023 Oct 12. doi: 10.1002/pros.24628. PubMedAbstract available
WANG L, Lyu C, Stadlbauer B, Buchner A, et al Berbamine targets cancer stem cells and reverses cabazitaxel resistance via
inhibiting IGF2BP1 and p-STAT3 in prostate cancer.
Prostate. 2023 Oct 12. doi: 10.1002/pros.24632. PubMedAbstract available
HOANG T, Sutera P, Nguyen T, Chang J, et al TP53 structure-function relationships in metastatic castrate-sensitive prostate
cancer and the impact of APR-246 treatment.
Prostate. 2023 Oct 9. doi: 10.1002/pros.24629. PubMedAbstract available
LABRECQUE MP, Brown LG, Coleman IM, Nguyen HM, et al Targeting the fibroblast growth factor pathway in molecular subtypes of
castration-resistant prostate cancer.
Prostate. 2023 Oct 5. doi: 10.1002/pros.24630. PubMedAbstract available
September 2023
ARAFA MA, Farhat KH, Khan FK, Rabah DM, et al Development and internal validation of a nomogram predicting significant prostate
cancer: Is it clinically applicable in low prevalent prostate cancer countries? A
multicenter study.
Prostate. 2023 Sep 27. doi: 10.1002/pros.24625. PubMedAbstract available
RAJWA P, Heidenreich J, Drzezga A, Schmidt M, et al The diagnostic accuracy of (68) Ga-PSMA-PET/CT in primary staging of patients
with high-risk nonmetastatic prostate cancer treated with radical prostatectomy:
A single-center cohort analysis.
Prostate. 2023 Sep 26. doi: 10.1002/pros.24627. PubMedAbstract available
ZOU P, Chen Z, He Q, Zhuo Y, et al Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells
through the ERK/DNMT1/ACSL4 axis.
Prostate. 2023 Sep 26. doi: 10.1002/pros.24626. PubMedAbstract available
KOELKER M, Labban M, Frego N, Ye J, et al Racial differences in patient-reported outcomes among men treated with radical
prostatectomy for prostate cancer.
Prostate. 2023 Sep 14. doi: 10.1002/pros.24624. PubMedAbstract available
ULERI A, Baboudjian M, Tedde A, Rajwa P, et al The association between beta-blockers use and prostate cancer mortality: A mini
systematic review and meta-analysis.
Prostate. 2023 Sep 14. doi: 10.1002/pros.24623. PubMedAbstract available
YAMADA Y, Sakamoto S, Sato K, Saito S, et al Clinical utility of the prognostic nutritional index in patients with metastatic
hormone-sensitive prostate cancer: A retrospective, multicenter, cohort study.
Prostate. 2023 Sep 10. doi: 10.1002/pros.24619. PubMedAbstract available
ESEN B, Seymen H, Gurses B, Armutlu A, et al The role of PSMA PET/CT to predict upgrading in patients undergoing radical
prostatectomy for ISUP grade group 1 prostate cancer.
Prostate. 2023 Sep 3. doi: 10.1002/pros.24621. PubMedAbstract available
FUJIWARA S, Kosaka T, Nishimoto Y, Kamisawa K, et al Prognostic significance of serum testosterone level in patients with
castration-resistant prostate cancer treated with cabazitaxel.
Prostate. 2023 Sep 3. doi: 10.1002/pros.24620. PubMedAbstract available
FRANCOLINI G, Banini M, Di Cataldo V, Detti B, et al PSMA guided approach for bIoCHEmical relapse after prostatectomy- (PSICHE) trial
(NCT05022914). Detection rate and treatment decision after 68Ga-PSMA PET/CT
within a prospective study.
Prostate. 2023;83:1201-1206. PubMedAbstract available